Merck & Co has expanded its clinical development programme for tulisokibart (MK-7240), adding phase IIb trials for a trio of immune-mediated inflammatory diseases.
Merck & Co has expanded its clinical development programme for tulisokibart (MK-7240), adding phase IIb trials for a trio of immune-mediated inflammatory diseases.